X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2189) 2189
science & technology (1827) 1827
life sciences & biomedicine (1785) 1785
bortezomib (1388) 1388
male (1324) 1324
female (1190) 1190
pyrazines - therapeutic use (1135) 1135
middle aged (1101) 1101
pyrazines - adverse effects (1084) 1084
aged (930) 930
pyrazines - administration & dosage (923) 923
multiple myeloma - drug therapy (777) 777
adult (755) 755
boronic acids - adverse effects (671) 671
oncology (669) 669
boronic acids - administration & dosage (654) 654
boronic acids - therapeutic use (620) 620
treatment outcome (607) 607
hematology (536) 536
multiple myeloma (524) 524
antineoplastic combined chemotherapy protocols - therapeutic use (470) 470
pyrazines - pharmacology (442) 442
antineoplastic agents - therapeutic use (440) 440
sitagliptin phosphate (413) 413
animals (410) 410
antineoplastic agents - adverse effects (402) 402
diabetes mellitus, type 2 - drug therapy (345) 345
aged, 80 and over (298) 298
care and treatment (298) 298
antineoplastic combined chemotherapy protocols - adverse effects (297) 297
pharmacology & pharmacy (287) 287
triazoles - therapeutic use (268) 268
dexamethasone - administration & dosage (233) 233
drug therapy, combination (233) 233
hypoglycemic agents - therapeutic use (231) 231
drug therapy (218) 218
research (218) 218
dose-response relationship, drug (215) 215
thalidomide - analogs & derivatives (213) 213
abridged index medicus (206) 206
triazoles - adverse effects (198) 198
boronic acids - pharmacology (197) 197
antineoplastic agents - administration & dosage (195) 195
medicine & public health (192) 192
cancer (188) 188
thalidomide - administration & dosage (188) 188
endocrinology & metabolism (186) 186
type 2 diabetes (184) 184
drug administration schedule (182) 182
recurrence (180) 180
clinical trials as topic (173) 173
sitagliptin (166) 166
mice (164) 164
protease inhibitors - therapeutic use (163) 163
hypoglycemic agents - adverse effects (162) 162
hematology, oncology and palliative medicine (155) 155
diabetes (153) 153
dosage and administration (152) 152
multiple myeloma - pathology (151) 151
proteasome inhibitors (151) 151
thalidomide - therapeutic use (151) 151
retrospective studies (142) 142
clinical trials (140) 140
pyrazines - pharmacokinetics (140) 140
dipeptidyl-peptidase iv inhibitors - therapeutic use (137) 137
disease-free survival (137) 137
double-blind method (137) 137
analysis (135) 135
triazoles - administration & dosage (134) 134
multiple myeloma - mortality (133) 133
antineoplastic agents - pharmacology (130) 130
chemotherapy (128) 128
general & internal medicine (128) 128
time factors (128) 128
medicine, general & internal (123) 123
multiple myeloma - therapy (122) 122
follow-up studies (121) 121
risk factors (120) 120
hypoglycemic agents - administration & dosage (119) 119
antineoplastic combined chemotherapy protocols - administration & dosage (117) 117
protease inhibitors - adverse effects (116) 116
thalidomide - adverse effects (116) 116
multiple myeloma - complications (115) 115
peripheral nervous system diseases - chemically induced (114) 114
dexamethasone (113) 113
transplantation (113) 113
diabetes mellitus, type 2 - blood (112) 112
prognosis (112) 112
survival analysis (109) 109
hemic and lymphatic diseases (107) 107
rats (104) 104
health aspects (103) 103
thalidomide (103) 103
adolescent (99) 99
melphalan - administration & dosage (98) 98
dexamethasone - adverse effects (97) 97
young adult (97) 97
dipeptidyl-peptidase iv inhibitors - adverse effects (96) 96
internal medicine (96) 96
blood glucose - metabolism (95) 95
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2281) 2281
Japanese (47) 47
Chinese (35) 35
German (27) 27
French (20) 20
Italian (11) 11
Spanish (11) 11
Russian (5) 5
Swedish (5) 5
Polish (4) 4
Czech (3) 3
Danish (3) 3
Hebrew (2) 2
Norwegian (2) 2
Portuguese (2) 2
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 12/2008, Volume 22, Issue 12, pp. 2247 - 2256
...) and its effect on bone remodeling and angiogenesis in relapsed/refractory myeloma. Bortezomib (1.0 mg/m(2)) was given on days 1, 4, 8, 11, oral melphalan... 
Neovascularization, Physiologic - drug effects | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Bone Remodeling - drug effects | Bone and Bones - drug effects | Antineoplastic Agents, Hormonal - adverse effects | Multiple Myeloma - drug therapy | Melphalan - adverse effects | Bone and Bones - metabolism | Aged, 80 and over | Adult | Female | Boronic Acids - administration & dosage | Immunosuppressive Agents - administration & dosage | Multiple Myeloma - physiopathology | Biomarkers - metabolism | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Cytokines - metabolism | Antineoplastic Agents, Hormonal - administration & dosage | Survival Rate | Thalidomide - administration & dosage | Multiple Myeloma - metabolism | Melphalan - administration & dosage | Pyrazines - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Antineoplastic Agents, Alkylating - adverse effects | Antimitotic agents | Multiple myeloma | Physiological aspects | Genetic aspects | Dosage and administration | Drug therapy, Combination | Neovascularization | Research | Drug therapy | Antineoplastic agents | Health aspects | Index Medicus
Journal Article
Blood, ISSN 1528-0020, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 1935-5548, 08/2014, Volume 37, Issue 8, pp. 2149 - 2158
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 07/2011, Volume 118, Issue 3, pp. 535 - 543
Journal Article
Blood, ISSN 1528-0020, 05/2016, Volume 127, Issue 20, pp. 2411 - 2415
Journal Article
Journal Article
Postgraduate medicine, ISSN 0032-5481, 05/2013, Volume 125, Issue 3, pp. 7 - 20